NCT02125292

Brief Summary

The purpose of this study is to compare the palatability of SHP429 capsule contents delivered via 3 means of administration (sprinkled on yogurt, sprinkled on applesauce, and emptied into a cup and administered with water).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
18

participants targeted

Target at below P25 for phase_1 healthy

Timeline
Completed

Started Jun 2014

Shorter than P25 for phase_1 healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 25, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 29, 2014

Completed
1 month until next milestone

Study Start

First participant enrolled

June 2, 2014

Completed
17 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 19, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 19, 2014

Completed
10 months until next milestone

Results Posted

Study results publicly available

April 20, 2015

Completed
Last Updated

June 3, 2021

Status Verified

May 1, 2021

Enrollment Period

17 days

First QC Date

April 25, 2014

Results QC Date

March 12, 2015

Last Update Submit

May 13, 2021

Conditions

Outcome Measures

Primary Outcomes (4)

  • Number of Participants With Positive Responses to Palatability Assessment of The Taste of Mesalamine

    A taste assessment was completed immediately after investigational product was administered to assess the subject's taste/liking of the formulation. The assessment consisted of a 5-point rating scale. Participants were asked to choose one of the following responses to the statement "The taste was acceptable": strongly agree, agree, neutral, disagree, or strongly disagree. The number of participants who chose either of the top two responses (strongly agree, agree) is reported.

    Immediately post-dose

  • Number of Participants Who Detected an Aftertaste of Mesalamine

    An aftertaste assessment was completed 5 minutes after administration of investigational product to assess whether the participants detected an aftertaste. The participants answered "Yes" or "No" to the following question: "Was there an aftertaste?" The number of participants who answered "Yes" is reported.

    5 minutes post-dose

  • Number of Participants With Positive Responses to Palatability Assessment of The Aftertaste of Mesalamine

    An aftertaste assessment was completed 5 minutes after administration of investigational product to assess the subject's rating of aftertaste and means of administration. The assessment consisted of a 5-point rating scale. The participants were asked to choose one of the following responses to the statement "The aftertaste (if present) was acceptable": strongly agree, agree, neutral, disagree, or strongly disagree. The number of participants who chose either of the top two responses (strongly agree, agree) is reported.

    5 minutes post-dose

  • Number of Participants Willing to Take Mesalamine Via Treatment Method on a Regular Basis

    The participants were asked to answer "Yes" or "No" to the following question: "Would you be willing to take medicine this way on a regular basis if necessary?" The number of participants who answered "Yes" is reported.

    Immediately post-dose

Secondary Outcomes (4)

  • Number of Participants Who Experienced an Adverse Event

    4 days

  • Number of Participants With Potentially Clinically Important Laboratory Results

    1 day

  • Number of Participants With Potentially Clinically Important Vital Signs

    1 day

  • Number of Participants With Potentially Clinically Important Electrocardiogram (ECG) Results

    1 day

Study Arms (3)

Mesalamine (Vanilla Yogurt)

EXPERIMENTAL

One 500mg capsule contents sprinkled onto 1 tablespoon of low-fat vanilla yogurt

Drug: Mesalamine

Mesalamine (Applesauce)

EXPERIMENTAL

One 500mg capsule contents sprinkled onto 1 tablespoon of applesauce

Drug: Mesalamine

Mesalamine (Dosing Cup)

EXPERIMENTAL

One 500mg capsule contents emptied into a dosing cup and taken with water

Drug: Mesalamine

Interventions

Also known as: Pentasa, SHP429
Mesalamine (Applesauce)Mesalamine (Dosing Cup)Mesalamine (Vanilla Yogurt)

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • normal, healthy, adult male and female volunteers, without evidence of active or chronic disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinical Pharmacology of Miami, Inc.

Miami, Florida, 33014, United States

Location

MeSH Terms

Interventions

Mesalamine

Intervention Hierarchy (Ancestors)

meta-AminobenzoatesAminobenzoatesBenzoatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsAminosalicylic AcidsSalicylatesHydroxybenzoatesHydroxy AcidsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPhenols

Results Point of Contact

Title
Study Director
Organization
Shire

Study Officials

  • Study Director

    Takeda

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 25, 2014

First Posted

April 29, 2014

Study Start

June 2, 2014

Primary Completion

June 19, 2014

Study Completion

June 19, 2014

Last Updated

June 3, 2021

Results First Posted

April 20, 2015

Record last verified: 2021-05

Locations